Optimized Radiological Diagnosis of Hepatic Candidiasis During the Treatment of Acute Leukemias

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IVSupportive careCompleted16 to 80Otheridr-3d-001
NCT01207843

Trial Description

Summary

Hepatic candidiasis is a frequent complication in patients receiving intensive chemotherapy for acute leukemia. Hepatic lesions may be detected by computerized tomographic (CT) scans, but there is no standardized CT protocol for the diagnosis and follow-up of hepatic candidiasis.

The investigators compared the size of the fungal lesions in the chest and abdomen CT. The current analysis aimed to increase the value of CT for the diagnosis and the follow-up of hepatic candidiasis in daily routine.

Eligibility Criteria

Inclusion criteria:

  • Chest and Abdomen CT with fungal lesion in patients with leukemia

Exclusion criteria:

  • Other liver pathologies

Trial Contact Information

Trial Lead Organizations/Sponsors

UniversitaetsSpital Zuerich

    Thomas Frauenfelder, MD, Principal Investigator

    Link to the current ClinicalTrials.gov record.
    NLM Identifier NCT01207843
    ClinicalTrials.gov processed this data on October 19, 2014

    Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.